Related Experiment Video
Updated: May 17, 2026
Microfluidics in Assessing Platelet Function
Published on: November 8, 2024
Evaluation of platelet aggregability during left ventricular bypass using a MedTech MagLev VAD in a series of chronic
Taro Kimura1, Yoshimasa Yokoyama, Daisuke Sakota
1Department of Biodesign, Institute of Biomaterials and Bioengineering, Tokyo Medical and Dental University, 2-3-10 Kanda-Surugadai, Chiyoda-ku, Tokyo, 101-0062, Japan. t_kimura_s@hotmail.co.jp
Insights
Continuous flow left ventricular assist device (LVAD) pumping significantly impacts platelet aggregation. An initial decrease in platelet aggregation is crucial for successful long-term mechanical circulatory support outcomes.
Area of Science:
- Biomedical Engineering
- Cardiovascular Science
- Hematology
Background:
- Continuous flow left ventricular assist devices (LVADs) are critical for managing advanced heart failure.
- Understanding device-biomaterial interactions, particularly on blood components, is essential for improving patient outcomes.
- Platelet function is a key determinant of thrombotic and hemostatic balance during mechanical circulatory support.
Purpose of the Study:
- To investigate the effect of a specific continuous flow LVAD (MedTech MagLev) on platelet aggregation in a preclinical model.
- To determine if the initial changes in platelet aggregation correlate with the success of long-term LVAD support.
- To evaluate the influence of anticoagulation and antiplatelet therapies on LVAD-induced platelet responses.
Main Methods:
- Animal model using six calves with a MagLev centrifugal blood pump implanted.
- Measurement of platelet aggregability using a turbidimetric assay during preoperative, operative, and postoperative phases.
- Administration of heparin, warfarin for anticoagulation, and aspirin for antiplatelet therapy.
Main Results:
- A significant decrease in platelet aggregation was observed immediately after LVAD initiation in experiments with successful long-term pump operation.
- Failure to observe this initial decrease in platelet aggregation was associated with coagulation-related complications, leading to experiment termination.
- Platelet aggregability was demonstrably affected by the LVAD pumping, with initial trends indicating prognostic value.
Conclusions:
- Continuous flow LVAD pumping has a significant impact on platelet aggregability.
- The initial trend of platelet aggregation post-LVAD implantation may predict the long-term success and complication-free duration of mechanical circulatory support.
- Monitoring platelet response is vital for optimizing anticoagulation and antiplatelet strategies in LVAD therapy.
Abstract:
The impact of continuous flow left ventricular assist device (LVAD) pumping on platelet aggregation was investigated in animal experiments utilizing six calves. A single-use MagLev centrifugal blood pump, MedTech MagLev, was used to bypass the calves' hearts from the left atrium to the descending aorta at a flow rate of 50 ml/kg/min. The LVAD's impact on blood coagulation activities was evaluated based on the platelet aggregability, which was measured with a turbidimetric assay method during the preoperative, operative, and postoperative periods. Heparin and warfarin were used for anticoagulation, while aspirin was used for the antiplatelet therapy. A decrease in platelet aggregation immediately after the pump started was observed in the cases of successful long-term pump operation, while the absence of such a decrease might have caused coagulation-related complications to terminate the experiments. Thus, the platelet aggregability was found to be significantly affected by the pump, and its initial trend may be related to the long-term outcome of the mechanical circulatory support.
